Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (301-310 of 448) with videos related to

Pageof 45
Sort By:
Rheumatology (Oxford, England)|February 5, 2017
The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) studyOtylia Kowal-Bielecka, Sylwia Chwiesko-Minarowska, Pawel L Bernatowicz, et al.
Annals of the Rheumatic Diseases|March 6, 2026
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case seriesMarc Scherlinger, Yannick Dieudonné, Stéphane Hilliquin, et al.
Journal of Autoimmunity|February 5, 2014
International consensus criteria for the diagnosis of Raynaud's phenomenonEmanual Maverakis, Forum Patel, Daniel G Kronenberg, et al.
Rheumatology (Oxford, England)|February 17, 2022
Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?Amber Vanhaecke, Maurizio Cutolo, Oliver Distler, et al.
Autoimmunity Reviews|December 16, 2019
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR databaseCamelia Frantz, Dorte Huscher, Jérôme Avouac, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Rheumatology (Oxford, England)|November 22, 2022
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysisCorrado Campochiaro, Anna-Maria Hoffmann-Vold, Jerome Avouac, et al.
The Lancet. Respiratory Medicine|September 1, 2020
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
The European Respiratory Journal|July 20, 2019
IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosisAnna Birnhuber, Slaven Crnkovic, Valentina Biasin, et al.
Journal of Clinical Medicine|January 11, 2024
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic SclerosisLuna Gargani, Cosimo Bruni, Giancarlo Todiere, et al.
Pageof 45

Showing results (301-310 of 448) with videos related to

Sort By:
Pageof 45
Rheumatology (Oxford, England)|February 5, 2017
The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) studyOtylia Kowal-Bielecka, Sylwia Chwiesko-Minarowska, Pawel L Bernatowicz, et al.
Annals of the Rheumatic Diseases|March 6, 2026
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case seriesMarc Scherlinger, Yannick Dieudonné, Stéphane Hilliquin, et al.
Journal of Autoimmunity|February 5, 2014
International consensus criteria for the diagnosis of Raynaud's phenomenonEmanual Maverakis, Forum Patel, Daniel G Kronenberg, et al.
Rheumatology (Oxford, England)|February 17, 2022
Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?Amber Vanhaecke, Maurizio Cutolo, Oliver Distler, et al.
Autoimmunity Reviews|December 16, 2019
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR databaseCamelia Frantz, Dorte Huscher, Jérôme Avouac, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Rheumatology (Oxford, England)|November 22, 2022
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysisCorrado Campochiaro, Anna-Maria Hoffmann-Vold, Jerome Avouac, et al.
The Lancet. Respiratory Medicine|September 1, 2020
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
The European Respiratory Journal|July 20, 2019
IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosisAnna Birnhuber, Slaven Crnkovic, Valentina Biasin, et al.
Journal of Clinical Medicine|January 11, 2024
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic SclerosisLuna Gargani, Cosimo Bruni, Giancarlo Todiere, et al.
Pageof 45